Margolis S A, Howell B F, Schaffer R
Clin Chem. 1977 Sep;23(9):1581-4.
The presence of a new lactate dehydrogenase inhibitor on the trailing edge of the NADH peak from chromatography on diethylaminoethyl-celluose [Loshon et al., Clin. Chem., this issue] was verified. It was resolved from the NADH by high-performance liquid chromatography on muBondapak C18. When the new inhibitor was present in a reaction mixture to the extent that, of the initial 260-nm absorbance, about 5% was contributed by the inhibitor, the rate of NADH oxidation by lactate dehydrogenase decreased by 65%. The inhibitor absorbs at 260 and 340 nm, and is different from the Strandjord-Clayson inhibitor [J. Lab. Clin. Med. 67, 144 (1966)] by both types of chromatography. Because this new inhibitor has ultraviolet properties similar to those of NADH and chromatographs with the NADH on DEAE-cellulose, the high-performance liquid chromatographic method must be used to ensure its absence in preparations of NADH used for clinical assay.
已证实存在一种新的乳酸脱氢酶抑制剂，它出现在二乙氨基乙基纤维素色谱法测定的NADH峰的后沿处[洛申等人，《临床化学》，本期]。通过在μBondapak C18上进行高效液相色谱法，它与NADH得以分离。当新抑制剂在反应混合物中的含量达到使初始260nm吸光度中约5%由该抑制剂贡献时，乳酸脱氢酶催化的NADH氧化速率降低了65%。该抑制剂在260和340nm处有吸收，并且通过两种色谱法都与斯特兰德乔德 - 克莱森抑制剂[《实验室与临床医学杂志》67, 144 (1966)]不同。由于这种新抑制剂具有与NADH相似的紫外特性，且在DEAE - 纤维素上与NADH一起被色谱分离，所以必须使用高效液相色谱法来确保用于临床检测的NADH制剂中不存在该抑制剂。
